2021
DOI: 10.1111/head.14067
|View full text |Cite
|
Sign up to set email alerts
|

Systematic review of outcomes and endpoints in acute migraine clinical trials

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
36
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 37 publications
(41 citation statements)
references
References 23 publications
0
36
0
Order By: Relevance
“…Further understanding of the impact of stigma on the lived experience of migraine is also critical to ensure that patients do not feel judged for their migraine‐induced debilitations or lessen their self‐worth due to their disease 34,37 . As reflected by recent expert international consensus 44 and systematic reviews, 45,46 clinical trials should always include outcomes that reflect the full impact of migraine on patient lives through assessing both disability and quality of life. Both disability and quality of life are worthy of being a primary outcome, including for pharmacological treatments as well as for implementation science and nonpharmacological treatment approaches 20,44,47 …”
Section: Discussionmentioning
confidence: 99%
“…Further understanding of the impact of stigma on the lived experience of migraine is also critical to ensure that patients do not feel judged for their migraine‐induced debilitations or lessen their self‐worth due to their disease 34,37 . As reflected by recent expert international consensus 44 and systematic reviews, 45,46 clinical trials should always include outcomes that reflect the full impact of migraine on patient lives through assessing both disability and quality of life. Both disability and quality of life are worthy of being a primary outcome, including for pharmacological treatments as well as for implementation science and nonpharmacological treatment approaches 20,44,47 …”
Section: Discussionmentioning
confidence: 99%
“…Implementing PROMs in real life has additional challenges, such as choosing the ideal set of PROMs to provide useful information while trying to keep the evaluation short and not bothersome, but also ensuring that patients fulfill them adequately, which may imply the help of an assistant or nurse, resulting in extra costs. In a more conceptual perspective, it is very challenging to define clinical meaningful change in PROMs results and even to be able to comprehensively englobe patients’ experiences in disorders that involve a multitude of concepts, as was recently exposed in a systematic review (12). Also, accepting PROMs as endpoints may be problematic because achieving one goal doesn’t mean that the patients’ problem is solved – by reaching a milestone, patients’ priorities in health goals change, and we may need another PROM to capture it (13).…”
Section: Discussionmentioning
confidence: 99%
“…Patient-reported outcome measures (PROMs) play an increasingly important role in the field of neurology, particularly in headache medicine (10)(11)(12)23). There are several PROMs currently seeing wide use in headache studies and clinical trials, such as the Migraine Disability Assessment Test (MIDAS), the 6-item Headache Impact Test (HIT-6), the Migraine-specific Quality of Life Questionnaire (MSQ) (24)(25)(26)(27)(28)(29). These existing PROMs provide valuable insights on domains such as headache-related disability and quality of life.…”
Section: Discussionmentioning
confidence: 99%